Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk
Authors:
- 3 December 2019
- journal article
- letter
- Published by Wolters Kluwer Health in Circulation
- Vol. 140 (23) , 1957-1959
Abstract
Optimal antithrombotic therapy after percutaneous coronary interventions in high bleeding risk (HBR) patients is an important issue under active discussion. However, no previous study has compared ...Keywords
This publication has 5 references indexed in Scilit:
- Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary InterventionCirculation, 2019
- Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCIJAMA, 2019
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSEuropean Heart Journal, 2017
- Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding RiskNew England Journal of Medicine, 2015
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJACC, 1988